Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...

Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track ...

M&A dealmaking activity is about to boom, according to Goldman Sachs. Here's how you can leverage that for index-beating ...

The United States market has been flat over the last week but is up 32% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks can ...

Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s treatment for classic galactosemia.

Hailing from Belgharia in Kolkata, 22-year-old Sayan Ghosh had traveled to Bangladesh on November 23. He stayed with a friend’s family.

Nov. 28, 2024 — The increased use of a chemical compound to replace TNT in explosive devices has a damaging and long lasting effect on plants, new research has ... Global Food Yields Have Grown ...